Journal of Agricultural and Food Chemistry
Cure8 research brief
Why This Matters
This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward microbiome-targeted IBD therapies.
Who Should Pay Attention
Researchers in microbiome and immune-pathway research, clinicians following IBD therapeutic research, and patients interested in microbiome-based approaches.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper reports laboratory and mouse-model research showing that extracellular vesicles (EVs) derived from the probiotic strain Lacticaseibacillus rhamnosus ZFML003 reduced inflammation and improved intestinal barrier markers in cell cultures, DSS-colitis mice, and organoid models.
The authors used multi-omics analyses and identify activation of PPARγ signaling as a necessary mechanism: pharmacologic PPARγ blockade (GW9662) removed the protective effects. The findings are preclinical: experiments were done in cells, mice, and organoids rather than in people.
The work suggests a possible microbiome-derived therapeutic approach that acts through PPARγ and alters gut microbial and metabolic profiles, but it does not demonstrate safety or effectiveness in patients.
If you have IBD, this is mechanistic research that points to future directions (microbiome-based products or PPARγ-targeted strategies) rather than an available treatment. Talk with your care team before changing any therapies or trying unproven probiotic products.
Keep In Mind
Findings come from cell, mouse (DSS-colitis), and organoid models and are reported in the article abstract; human safety and efficacy are not established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of Agricultural and Food Chemistry
PublisherAmerican Chemical Society (ACS)
AuthorsYingjie Huang, La Xi, Bin Yu +7 more
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 11, 2026, 12:00 AM
Content availableJournal abstract
Funding disclosed by the source: National Basic Research Program of China (973 Program), award 2024YEF0111400; National Natural Science Foundation of China (NSFC), award 32272301
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Extracellular Vesicles Derived from Elaeocarpus braceanus Alleviate DSS-Induced Ulcerative Colitis in Mice Through Multiple Pathways
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
Extracellular Vesicles Derived from Elaeocarpus braceanus Alleviate DSS-Induced Ulcerative Colitis in Mice Through Multiple Pathways.
The study suggests a novel plant-derived nanoparticle approach reduced inflammation and repaired barrier function in a mouse model of colitis and changed the gut microbiome — a potential early-stage route for new IBD...
A natural pectic polysaccharide from rhubarb reprograms dysbiotic gut microbiota and resolves mucosal inflammation in ulcerative colitis.
People with ulcerative colitis may be interested because the study describes a natural compound that reduced inflammation and disease signs in a mouse model and acted through the gut microbiota and immune pathways —...